With the identification of autoantigens in various autoimmune diseases, the use of self-peptide vaccines in the prevention and treatment of autoimmunity is becoming a possiblity. However, anaphylaxis has been observed with the use of self-peptides in experimental autoimmune encephalitis (EAE) and we have observed fatal anaphylaxis in type 1 diabetes in mice. Recently, a phase II trial of an altered peptide ligand in multiple sclerosis has also been complicated by hypersensitivity reactions. Finally, there is an altered peptide ligand trial for the insulin B:9-23 peptide (amino acids 9 through 23 on the insulin B chain) for type 1 diabetes currently underway in man. Insulin peptide B:9-23 is a major autoantigen in type 1 diabetes. Treatment of NOD mice with subcutaneous B:9-23 peptide in saline protects from diabetes, but is associated with fatal anaphylaxis upon repeated administration. The purpose of this project is to evaluate a potential general mechanism to prevent peptide-induced anaphylaxis while preserving immunomodulation as it relates primarily to a vaccine for type 1 diabetes utilizing B:9-23. It is hypothesized that rapid systemic absorption of subcutaneous B:9-23 can be delayed by neutralizing the pl, avoiding anaphylaxis while retaining its immunologic properties. Preliminary data includes altering the pl of B:9-23 through the addition of 2 arginines (RR) at the C-terminus, changing the pl from 5.3 to near neutral.
The specific aims are to i) confirm the ability of B:9-23RR to prevent anaphylaxis when injected subcutaneously but not intravenously ii) directly quantitate the systemic absorption of B:9-23 and B:9-23RR and correlate this with the occurrence of anaphylaxis iii) quantitate the isotype-specific anti-insulin and anti-peptide antibodies following B:9-23 and B:9-23RR administration iv) confirm/characterize the ability of B:9-23RR to prevent diabetes and determine if cells that block diabetes transfer have been induced v) test the generalization that B:9-23 modified to have a neutral pl prevents anaphylaxis by testing alternative C-terminus extensions of B:9-23 and finally vi) Generalize this mechanism of altered pl to a model of EAE to determine if peptide anaphylaxis seen in EAE can also be prevented with modified peptides. It is hypothesized that alteration of the pl of peptides may be a generalizable technique to prevent peptide-induced anaphylaxis while retaining immunomodulatory capacity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK064605-04
Application #
7091491
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2003-07-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
4
Fiscal Year
2006
Total Cost
$129,330
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Eisenbarth, George S (2010) Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 59:759-74
Zhang, Li; Nakayama, Maki; Eisenbarth, George S (2008) Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 20:111-8
Barker, Jennifer M; Liu, Edwin (2008) Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr 55:349-65
Liu, Edwin; Eisenbarth, George S (2007) Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 125:120-6
Nakayama, Maki; Beilke, Joshua N; Jasinski, Jean M et al. (2007) Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117:1835-43
Jasinski, Jean M; Yu, Liping; Nakayama, Maki et al. (2006) Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 55:1978-84